Skip to main content

What the FDA labels say about taking them together

Dolutegravir and phenobarbital

Dolutegravir's FDA label of May 22, 2026 names phenobarbital in its drug interactions section; the phenobarbital labels PlainMeds reads (2) do not name dolutegravir. The dolutegravir label: “Avoid coadministration with TIVICAY or TIVICAY PD because there are insufficient data to make dosing recommendations.”

Check it at the source: the dolutegravir FDA label on DailyMed (effective May 22, 2026, ST. MARY'S MEDICAL PARK PHARMACY); the phenobarbital FDA label on DailyMed (effective August 27, 2026).

What does the dolutegravir label say about phenobarbital?

Dolutegravir label, drug interactions

Concomitant Drug Class/Drug Name: Oxcarbazepine Phenytoin Phenobarbital St. John’s wort ( Hypericum perforatum); Effect on Concentration of Dolutegravir and/or Concomitant Drug: ↓Dolutegravir; Clinical Comment: Avoid coadministration with TIVICAY or TIVICAY PD because there are insufficient data to make dosing recommendations.

Source: FDA drug label (Tivicay), NDA204790 (Viiv Hlthcare), as published by ST. MARY'S MEDICAL PARK PHARMACY, effective May 22, 2026 (SPL set 485bc9db-8665-9f5a-e063-6394a90a7921), via openFDA; the full label on DailyMed

What does the phenobarbital label say about dolutegravir?

Phenobarbital's label (effective August 27, 2026) and its 1 other brand-application label do not name dolutegravir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Phenobarbital), Chartwell RX, LLC, effective August 27, 2026 (SPL set 74428144-fb24-40a5-a670-3b876e2d116c), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Dolutegravir generic labelers
0Phenobarbital generic labelers
DolutegravirPhenobarbital
Labeled forHIVSeizures and epilepsy
Boxed warningNoNo
Pharmacy cost (NADAC)$77.64 per tablet 50 mg tablet$0.213 per tablet 100 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?